SNAI1 and hepatocellular carcinoma: In a previous report, sorafenib was shown to exert potent inhibitory activity against EMT by inhibiting Snail expression via the MAPK signaling pathway in HCC cells [5], but it has also been reported that, in sorafenib-resistant HCC cells, EMT was accompanied by activation of the phosphoinositide 3-kinase (PI3K)/AKT pathway [14], indicating that the complicated role of EMT in sorafenib resistance is far from clear.